SG Americas Securities LLC cut its position in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 47.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,926 shares of the biopharmaceutical company’s stock after selling 12,763 shares during the period. SG Americas Securities LLC’s holdings in Juno Therapeutics were worth $416,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in JUNO. Teachers Advisors LLC boosted its stake in Juno Therapeutics by 12.3% during the fourth quarter. Teachers Advisors LLC now owns 60,834 shares of the biopharmaceutical company’s stock valued at $1,147,000 after buying an additional 6,643 shares during the last quarter. Nisa Investment Advisors LLC bought a new position in Juno Therapeutics during the first quarter valued at approximately $200,000. Wells Fargo & Company MN boosted its stake in Juno Therapeutics by 238.4% during the first quarter. Wells Fargo & Company MN now owns 121,392 shares of the biopharmaceutical company’s stock valued at $2,693,000 after buying an additional 85,516 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in Juno Therapeutics by 111.2% during the first quarter. Canada Pension Plan Investment Board now owns 94,400 shares of the biopharmaceutical company’s stock valued at $2,095,000 after buying an additional 49,700 shares during the last quarter. Finally, Great West Life Assurance Co. Can boosted its stake in Juno Therapeutics by 80.5% during the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 3,800 shares during the last quarter. 70.76% of the stock is owned by institutional investors.
In related news, Director Richard Klausner sold 12,000 shares of the business’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $42.66, for a total transaction of $511,920.00. Following the completion of the transaction, the director now owns 783,536 shares in the company, valued at $33,425,645.76. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Anthony B. Evnin bought 9,000 shares of the stock in a transaction that occurred on Tuesday, June 20th. The shares were purchased at an average price of $24.40 per share, with a total value of $219,600.00. Following the purchase, the director now owns 66,301 shares of the company’s stock, valued at approximately $1,617,744.40. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 8,078,369 shares of company stock valued at $218,620,477. Insiders own 15.26% of the company’s stock.
Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) opened at 42.15 on Wednesday. The company’s market cap is $4.42 billion. The firm’s 50-day moving average price is $32.40 and its 200 day moving average price is $26.57. Juno Therapeutics, Inc. has a 12 month low of $17.52 and a 12 month high of $44.60.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.24). The company had revenue of $21.30 million for the quarter, compared to analysts’ expectations of $15.59 million. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm’s revenue was down 22.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.64) EPS. Equities research analysts anticipate that Juno Therapeutics, Inc. will post ($3.12) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/09/13/sg-americas-securities-llc-reduces-position-in-juno-therapeutics-inc-juno.html.
A number of equities research analysts have issued reports on the company. Zacks Investment Research downgraded Juno Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 3rd. Morgan Stanley upped their price objective on Juno Therapeutics from $26.00 to $27.00 and gave the company an “equal weight” rating in a research report on Monday, August 7th. FBR & Co restated a “hold” rating on shares of Juno Therapeutics in a research report on Thursday, May 18th. Vetr downgraded Juno Therapeutics from a “buy” rating to a “hold” rating and set a $28.85 price objective on the stock. in a research report on Monday, June 26th. Finally, BidaskClub upgraded Juno Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 20th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $34.88.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics, Inc. (NASDAQ:JUNO).
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.